Online first
Letter to the Editor
Published online: 2024-08-14

open access

Page views 12
Article views/downloads 6
Get Citation

Connect on Social Media

Connect on Social Media

The effectiveness and safety of dasiglucagon in emergency medicine

Malgorzata Kietlinska1, Liudmyla Zakordonets2, Julia Krotofil3, Halla Kaminska4

Abstract

Non

Article available in PDF format

View PDF Download PDF file

References

  1. Tamaro G, Solidoro S, Tornese G. Dasiglucagon: A New Hope for Diazoxide-unresponsive, Nonfocal Congenital Hyperinsulinism? J Clin Endocrinol Metab. 2024; 109(7): e1548–e1549.
  2. American Diabetes Association Professional Practice Committee . Summary of Revisions: Standards of Care in Diabetes-2024. Diabetes Care. 2024; 47(Supplement_1): S5–SS10.
  3. Pieber TR, Aronson R, Hövelmann U, et al. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care. 2021; 44(6): 1361–1367.
  4. Giménez M, Khunti K, Matsuhisa M, et al. Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia. Diabetes Ther. 2023; 14(11): 1757–1769.
  5. Maji S, Mohanty RR, Maiti R. Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis. Balkan Med J. 2023; 40(6): 400–408.
  6. Dholariya S, Parchwani D, Dutta S, et al. Clinical efficacy and safety of dasiglucagon in severe hypoglycemia associated with patients of type 1 diabetes mellitus: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2023; 16(1): 61–71.
  7. Maji S, Mohanty RR, Maiti R. Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis. Balkan Med J. 2023; 40(6): 400–408.
  8. Laugesen C, Ranjan AG, Schmidt S, et al. Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial. Diabetologia. 2023; 66(7): 1208–1217.
  9. Demirbilek H, Vuralli D, Haris B, et al. Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies. Diabetes Metab Syndr Obes. 2023; 16: 259–273.